D.E. Shaw & Co’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,665,474
| Closed | -$15M | – | 5109 |
|
|
2025
Q4 | $15M | Buy |
1,665,474
+1,142,786
| +219% | +$8.54M | 0.01% | 1434 |
|
|
2025
Q3 | $1.63M | Buy |
522,688
+473,756
| +968% | +$1.26M | ﹤0.01% | 3125 |
|
|
2025
Q2 | $105K | Sell |
48,932
-17,261
| -26% | -$27.9K | ﹤0.01% | 4127 |
|
|
2025
Q1 | $76.1K | Buy |
66,193
+13,962
| +27% | +$24K | ﹤0.01% | 4043 |
|
|
2024
Q4 | $114K | Sell |
52,231
-54,437
| -51% | -$123K | ﹤0.01% | 4157 |
|
|
2024
Q3 | $233K | Buy |
106,668
+17,288
| +19% | +$39.8K | ﹤0.01% | 4091 |
|
|
2024
Q2 | $206K | Sell |
89,380
-106,734
| -54% | -$443K | ﹤0.01% | 4060 |
|
|
2024
Q1 | $1.08M | Sell |
196,114
-318,505
| -62% | -$1.46M | ﹤0.01% | 3043 |
|
|
2023
Q4 | $1.27M | Buy |
+514,619
| New | +$4.89M | ﹤0.01% | 2970 |
|
|
2023
Q3 | – | Sell |
-47,112
| Closed | -$1.55M | – | 4519 |
|
|
2023
Q2 | $1.55M | Sell |
47,112
-24,747
| -34% | -$853K | ﹤0.01% | 2812 |
|
|
2023
Q1 | $2.41M | Sell |
71,859
-16,500
| -19% | -$642K | ﹤0.01% | 2546 |
|
|
2022
Q4 | $2.9M | Sell |
88,359
-84,371
| -49% | -$2.5M | ﹤0.01% | 2620 |
|
|
2022
Q3 | $6.03M | Buy |
172,730
+154,787
| +863% | +$3.43M | 0.01% | 1878 |
|
|
2022
Q2 | $219K | Buy |
+17,943
| New | +$268K | ﹤0.01% | 4511 |
|
Other funds holding VTYX
D.E. Shaw & Co's VTYX Position: Q1 2026 in Review
D.E. Shaw & Co sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,665,474 shares — an estimated $15M sold.
D.E. Shaw & Co first reported a position in VTYX in Q2 2022 and held it in 14 quarters. The position peaked at $15M in Q4 2025. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- D.E. Shaw & Co reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- D.E. Shaw & Co sold 1,665,474 Ventyx Biosciences shares in Q1 2026, an estimated $15M.
- D.E. Shaw & Co first reported a position in Ventyx Biosciences in Q2 2022 and held it in 14 quarters.
- D.E. Shaw & Co's Ventyx Biosciences position peaked at $15M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.